Background: Hyperkalemia accounts for over 800,000 emergency department (ED) visits in the United States each year, and has been associated with significant morbidity and mortality likely due to fatal cardiac dysrhythmias. Previous studies have demonstrated reductions in mortality when potassium levels are normalized in the ED. Cation exchange resins, such as sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC), may be administered as a means of definitively eliminating potassium from the body. This practice is based on physician preference and is not supported by high quality data. Two studies evaluating the use of cation exchange resins versus standard treatment in the ED demonstrated reductions in serum potassium levels within two hours of administration; however, there have been no published studies investigating these agents in a head-to-head comparison.
Objective: The purpose of this study was to evaluate the efficacy and safety of SPS versus SZC in lowering serum potassium in patients presenting to the ED with hyperkalemia.
Methods: This was an institutional review board-approved, retrospective cohort study conducted at a single-site ED. All patients who received medications under the "ED Hyperkalemia Treatment" order set between August 26, 2019 and May 13, 2021 were eligible for inclusion. The primary outcome was the change in serum potassium from baseline to first repeat level following SPS or SZC administration in the ED.
Results: A total of 885 patients were screened with 54 patients in the SPS group and 51 patients in the SZC group included in the final analyses. The mean change in serum potassium from baseline to first repeat level following administration of the cation exchange resin was -1.1 mEq/L for both groups.
Conclusion: Administration of SPS or SZC for the treatment of hyperkalemia in the ED resulted in similar reductions in serum potassium.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2022.12.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: This clinical study assessed the three-year, long-term effects of esaxerenone, a non-steroidal aldosterone receptor blocker, on Japanese patients with type 2 diabetes, diabetic kidney disease, and hypertension who were receiving renin-angiotensin system inhibitors.
Materials And Methods: Data from a computerized diabetic care database were used to retrospectively compare esaxerenone users (Group A) with non-esaxerenone users (Group B). Propensity score weighting was applied to Group B.
Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice.
Card Fail Rev
December 2024
Department of Medicine, University of Mississippi Medical Center Jackson, MS, US.
Aldosterone is a key regulator of fluid and electrolyte balance in the body. It is often dysregulated in heart failure (HF) and is a key driver of cardiac remodelling and worse clinical outcomes. Potassium regulation is essential for normal cardiac, gastrointestinal and neuromuscular function.
View Article and Find Full Text PDFThe role of cation-exchange resins in hyperkalemia management.
Med J Armed Forces India
August 2024
Head of Nephrology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Jl. Prof. Dr. Moestopo No.47, Pacar Kembang, Kec. Tambaksari, Surabaya, Jawa Timur, Indonesia.
Hyperkalemia, characterized by elevated serum potassium levels, poses significant health risks, including life-threatening cardiac arrhythmias. The management of hyperkalemia has evolved, incorporating calcium polystyrene sulfonate (CPS) and newer agents such as sodium zirconium cyclosilicate (SZC) and patiromer alongside traditional treatments. This review provides a comprehensive examination of current management strategies for hyperkalemia, focusing on the comparative effectiveness, safety profiles, and patient preferences concerning CPS, SZC, and patiromer.
View Article and Find Full Text PDFFactors predicting secondary hypertension in young adults with hypertension: a retrospective study.
BMC Cardiovasc Disord
January 2025
Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Background: Hypertension in young adults is often due to secondary causes, and investigating these can be resource-intensive. This study aimed to identify clinical and biochemical markers that could suggest secondary hypertension in individuals under 40 years.
Materials And Methods: A 6-year retrospective observational cohort study included 207 young adults with hypertension who were assessed for secondary causes such as hyperthyroidism, primary aldosteronism, Cushing's syndrome, pheochromocytoma, and renovascular disease.
Short-term evaluation of renal biochemical parameters in dogs completing chemotherapy for lymphoma.
Aust Vet J
January 2025
North Shore Veterinary Specialist & Emergency Centre, Artarmon, New South Wales, Australia.
Objectives: To identify if chemotherapeutic drugs in the CHOP-based protocol led to an increase in renal parameters in dogs with lymphoma during therapy and investigate whether factors such as prednisolone use or age affected this result.
Methods: Data were obtained retrospectively from private referral practice records of dogs diagnosed with lymphoma receiving a CHOP-based chemotherapy protocol between 2015 and 2019. Dogs included received a CHOP-based protocol as their first treatment, received four full cycles and were in remission at the end of the protocol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!